A preliminary study of ritonavir, an inhibitor of hiv-1 protease, to treat hiv-1 infection

Martin Markowitz, Michael Saag, William G. Powderly, Arlene M. Hurley, Ann Hsu, Joaquin M. Valdes, David Henry, Fred Sattler, Anthony la Marca, John M. Leonard, David D. ho

Research output: Contribution to journalArticlepeer-review

459 Scopus citations

Abstract

Ritonavir is a potent inhibitor in vitro of human immunodeficiency virus type 1 (HIV-1) protease, which is needed for virions to mature and become infective. We assessed the safety and efficacy of ritonavir in patients with HIV-1 infection. We administered ritonavir orally to 62 patients in one of four dosages during a 12-week trial containing a 4-week randomized, placebo-controlled, double-blinded phase followed by an 8-week dose-blinded phase. We assessed the response with serial measurements of plasma viremia and serial CD4 cell counts. Fifty-two patients completed the 12-week trial. Diarrhea and nausea were the most common side effects, and reversible elevations in serum triglyceride and γ-glutamyltransferase levels were the most frequent laboratory abnormalities. Ritonavir had a rapid antiviral effect, with a mean maximal reduction in the number of copies of HIV-1 RNA per milliliter of plasma that ranged from 0.86 to 1.18 log in the four dosage groups. After 12 weeks of treatment, the antiviral effect was partially maintained, with a mean reduction in plasma viremia of 0.5 log. When we used a more sensitive assay for HIV-1 RNA in a subgroup of 20 patients, we found that plasma viremia decreased by a mean of 1.7 log. This antiviral effect was partly sustained at week 12, with a mean reduction of approximately 1.1 log. The patients' CD4 cell counts rose during treatment with ritonavir (median increase, 74 and 83 cells per cubic millimeter at weeks 4 and 12, respectively). The protease inhibitor ritonavir is well tolerated and has a potent antiviral effect, as shown by substantial decreases in plasma viremia and significant elevations in CD4 cell counts. Expanded clinical trials of ritonavir are warranted.

Original languageEnglish
Pages (from-to)1534-1540
Number of pages7
JournalNew England Journal of Medicine
Volume333
Issue number23
DOIs
StatePublished - Dec 7 1995

Fingerprint

Dive into the research topics of 'A preliminary study of ritonavir, an inhibitor of hiv-1 protease, to treat hiv-1 infection'. Together they form a unique fingerprint.

Cite this